Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors


Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.

Aim(s): Thus, we evaluated whether plasma CgA response to OT could predict the clinical response to SSAs.

Materials and methods: At diagnosis, 38 GEP-NET patients received octreotide 200 μg s.c., with plasma CgA determination at 0, 3 and 6 hours. Long-term SSA treatment was then given by monitoring clinical outcome.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Massironi S

Authors: Massironi S, Conte D, Sciola V, Spampatti M, Rossi R,

Keywords: gastroenteropancreatic neuroendocrine tumors, carcinoids, pancreatic endocrine tumors, chromogranin A, somatostatin analogues,

To read the full abstract, please log into your ENETS Member account.